Skip to main
  1. Stocks
  2. Immunic Inc
  3. Forecast
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is supported by a lead asset, vidofludimus calcium, that has Phase 2 evidence of relapse reduction, MRI lesion suppression, and durable disability control, while also showing a favorable safety and tolerability profile across 3500+ patients with no clear hepatotoxicity or serious infection signal. Its opportunity is amplified by a large MS market over $20B, meaningful unmet need in progression despite existing therapies, and a differentiated dual mechanism that may address both inflammation and neuroprotection, while EN SURE-1 and ENSURE-2 enrolled 1,121 and 1,100 patients and are expected to report topline by the end of 2026. Financially, the company also benefits from about $200MM gross PIPE proceeds in February 2026 and patent coverage that may extend to 2041-2045, which together improve runway visibility and protect long-term commercialization potential.

Bears say

Immunic is exposed to substantial clinical and regulatory risk because its lead asset, vidofludimus calcium, could fail to show sufficient efficacy or could face a safety signal that disrupts development or adoption. Even with 3500+ patients dosed and no observed increase in hepatotoxicity or serious infections to date, the bear-case analysis still implies weak commercial penetration, with modeled market share as low as 0.4% to 0.5% and valuation outcomes below $0.4B. The company also faces dilution risk from warrant exercise, possible manufacturing or shipment issues, and likely additional funding needs over a 3.5-4 year Phase 3 timeline, while competition from approved and generic DMTs limits sales upside.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Immunic Inc (IMUX) Analyst Forecast & Price Prediction

Get the latest Immunic Inc (IMUX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immunic Inc (IMUX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Immunic Inc (IMUX) Analyst Forecast & Price Prediction

Get the latest Immunic Inc (IMUX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immunic Inc (IMUX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IMUX stock data and trends